``We don't always understand the full magnitude of a drug's risks before it goes on the market,'' said Steven Galson, acting director of the FDA's Center for Drug Evaluation and Research, in a teleconference on the new initiatives.
Seven weeks before Merck &amp; Co. pulled the arthritis drug Vioxx off the market because of safety concerns, federal drug regulators downplayed the significance of scientific findings citing the increased risks, documents released Thursday show.
